


RESULTS OF EXTRAORDINARY GENERAL ASSEMBLY MEETING (FIRST MEETING 2026)



RESULTS OF EXTRAORDINARY GENERAL ASSEMBLY MEETING (FIRST MEETING 2026)

1. Approval of appointing Ernst & Young Professional Services (Professional LLC) as the company's external auditor from among the nominated candidates based on the recommendation of the Audit Committee to examine, review, and audit the consolidated financial statements for the first quarter of the fiscal year 2026, and to determine their fees for a total compensation of SAR 92,750 (Ninety-Two Thousand and Seven Hundred Fifty Saudi Riyals), exclusive of VAT.
2. Approval of the Board of Directors' recommendation to approve the Employee Share Program (Long-Term Incentive Plan) for the group's employees, and to authorize the Board to manage the plan, link its mechanism to performance, and make the necessary amendments as needed.
3. Approval of the Board of Directors' resolution to appoint (Dr. Zeyad Othman Al-Hekail) as an Independent Member of the Board of Directors, effective from his appointment date on November 4, 2025, to complete the current Board term until its expiry on December 31, 2027, replacing the former Non-Executive Member, (Mr. Noor Al-Rahman Abid).
4. Approval of delegating the Board of Directors with the powers of the Ordinary General Assembly to grant the license referred to in paragraph (1) of Article Twenty-Seven of the Companies Law, for a period of one year from the date of approval by the General Assembly or until the end of the term of the authorized Board of Directors, whichever comes first, in accordance with the conditions set forth in the Implementing Regulations of the Companies Law for Listed Joint Stock Companies.
5. Approval of the business and contracts to be entered into between Dr. Soliman Abdul Kader Fakeeh Hospital Company ("DSFH Jeddah") and Soliman Abdul Kader Fakeeh Real Estate Company, in which the Chairman of the Board, Mr. Ammar Soliman Abdul Kader Fakeeh, the Vice Chair of the Board, Dr. Manal Soliman Abdul Kader Fakeeh, and Board Member Dr. Mazen Soliman Abdul Kader Fakeeh have an indirect interest. The transaction relates to Dr. Soliman Abdul Kader Fakeeh Hospital Company ("DSFH Jeddah") acquiring a majority stake (50.01%) in Diagnostic Elite Company Ltd. for a total amount of SAR 70,000,000 (SAR 55.35 million payable to Fakeeh Real Estate Company and SAR 14.65 million to be injected as a capital contribution into Diagnostic Elite).